Beaufort Securities Reiterates “Speculative Buy” Rating for Amryt Pharma PLC (FAST)
Amryt Pharma PLC (LON:FAST)‘s stock had its “speculative buy” rating reaffirmed by research analysts at Beaufort Securities in a report released on Thursday. They currently have a GBX 62 ($0.80) price target on the stock.
Shares of Amryt Pharma PLC (FAST) opened at 2.97 on Thursday. Amryt Pharma PLC has a 1-year low of GBX 1.85 and a 1-year high of GBX 3.90. The company’s 50-day moving average is GBX 2.91 and its 200 day moving average is GBX 2.54.
TRADEMARK VIOLATION NOTICE: “Beaufort Securities Reiterates “Speculative Buy” Rating for Amryt Pharma PLC (FAST)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/beaufort-securities-reiterates-speculative-buy-rating-for-amryt-pharma-plc-fast/1537916.html.
About Amryt Pharma PLC
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.
Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.